Udho Thadani, MBBS; Claude R. Maranda, MD; Ezra Amsterdam, MD; Leo Spaccavento, MD; Richard G. Friedman, MD; Robert Chernoff, MD; Stephen Zellner, MD; Jeffrey Gorwit, MD; Paul H. Hinderaker, MD
Thadani U, Maranda CR, Amsterdam E, Spaccavento L, Friedman RG, Chernoff R, et al. Lack of Pharmacologic Tolerance and Rebound Angina Pectoris during Twice-Daily Therapy with Isosorbide-5-Mononitrate. Ann Intern Med. 1994;120:353-359. doi: 10.7326/0003-4819-120-5-199403010-00001
Download citation file:
Published: Ann Intern Med. 1994;120(5):353-359.
To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris.
Multicenter, placebo-controlled, parallel-group, double-blind, randomized study.
Four university teaching hospitals and five private cardiology outpatient clinics.
116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris.
After stopping all antianginal drugs with the exception of β-blockers, patients received single-blind placebo for 1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks.
Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks.
Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group.
Isosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Coronary Heart Disease, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only